The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.
Camargo
Eduardo G
EG
Weinert
Letícia S
LS
Lavinsky
Joel
J
Gross
Jorge L
JL
Silveiro
Sandra P
SP
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004311:Double-Blind Method; D004347:Drug Interactions; D004656:Enalapril / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000188:drug therapy* / Q000209:etiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D004656:Enalapril; D001241:Aspirin